Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01674283

Enrollment

Registered

2012-08-28

Start date

2013-10-31

Completion date

2013-10-31

Last updated

2015-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women With Fertility Disorder

Brief summary

The success of in vitro fertilization is based mainly on uterine implantation embryo. An excessive uterine contractility may interfere with implantation by a movement of the embryo in the uterus. The inhibition of the uterine contractility may have a positive effect on success rate of in vitro fertilization. It is through parenteral injection of glucagon and its spasmolytic effect on various smooth muscles and thereby on the uterine muscle, at the time of embryo transfer, the investigators intend to improve the pregnancy rates obtained after IVF.

Detailed description

Women will have a cycle of in vitro fertilization (IVF) and follow the standard protocol established by the clinic ovo or the fertility clinic of CHUM. On the day of embryo transfer, the investigators will administer 1 mg of Glucagon or placebo intramuscularly 10 minutes before the embryo transfer. The uterine contractility will be measured by ultrasound before and after injection to document the impact of Glucagon on it and we will proceed to embryo transfer.

Interventions

DRUGGlucagon

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Women doing fertility treatment at the clinic ovo or fertility clinic of CHUM * Less than 40 years old * Women with stimulate in vitro fertilization cycle * Women able to give her consent

Exclusion criteria

* Body mass index \> 35 kg/m2 * Women with diabetes * Women with hypertensive disorders * Women with a blood pressure greater or equal to 140/90 mmHg at the randomization visit * Cons-indication to taking Glucagon: * Hypersensitivity to product * Pheochromocytoma or history of pheochromocytoma * Insulinoma * Taking a beta-blocker (drug interactions)

Design outcomes

Primary

Measure	Time frame	Description
Uterine muscle relaxation	30 minutes	Determine if the intramuscular administration of 1mg of Glucagon 10 minutes before the embryo transfer is associated with a uterine muscle relaxation.

Secondary

Measure	Time frame	Description
Embryo implantation and pregnancy rate	7 weeks	Determine if the intramuscular administration of 1mg of Glucagon 10 minutes before the embryo transfer is associated with higher implantation and pregnancy rates than during embryo transfer without glucagon.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026